Lyn Ebert

Lyn Ebert

Auto-generated profile, based on publicly available information

Lyn Ebert

Faculty of Health Southern Cross University Southport New South Wales Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2018 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
JZJiemin ZHU
Jiemin ZHU
LELyn Ebert
Lyn Ebert
XLXiangyu Liu
Xiangyu Liu
DWDi Wei
Di Wei
Sally Wai Chi ChanSally Wai Chi Chan
Sally Wai Chi Chan
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

11 April 2018 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
JZJiemin ZHU
Jiemin ZHU
LELyn Ebert
Lyn Ebert
DGDongmei Guo
Dongmei Guo
SYSumei Yang
Sumei Yang
QHQiuying Han
Qiuying Han
Sally Wai Chi ChanSally Wai Chi Chan
Sally Wai Chi Chan
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.


22 July 2022 in Birth
Verified
Journal Article
Open access
LELyn Ebert
Lyn Ebert
DMDeb Massey
Deb Massey
TFTracy Flenady
Tracy Flenady
SNSamantha Nolan
Samantha Nolan
TDTrudy Dwyer
Trudy Dwyer
EJElaine Jefford
Elaine Jefford
Background: Early warning systems (EWS) are used across health care settings as a tool for the early identification of clinical deterioration and to determine the need to escalate care. Early detection of clinical deterioration and appropriate escalation of care in maternity settings is critical to the safety of pregnant women and infants; however, underutilization of EWS tools and reluctance to escalate care have been consistently reported. Little is known about midwives' use of EWS in the Australian context.Methods: Using a cross‐sectional approach, we elicited the attitudes, beliefs, and behaviors of a purposive sample of Australian midwives (n = 87) with respect to the Maternal Early Warning Trigger Tool (MEWT). Participants answered a 25‐question Likert scale survey and one open‐ended question. Qualitative answers were analyzed using consensus coding.Results: Midwives reported positive attitudes toward the MEWT, describing it as a valuable tool for identifying clinical deterioration, especially when used as an adjunct to clinical judgment. However, midwives also identified training gaps; 25% had received no training, and only half of those who had received training felt it was effective. In addition, professional tension can create a significant barrier to the effective use of the MEWT. Midwives also reported feeling influenced by their peers in their decision‐making with respect to use of the MEWT and being afraid they would be chastised for escalating care unnecessarily.Conclusions: Although the MEWT is valued by Australian midwives as a useful tool, barriers exist to its effective use. These include a lack of adequate, ongoing training and professional tension. Improving interdisciplinary collaboration could enhance the use of this tool for the safety of birthing women and their infants.

5 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JBJena Buchan
Jena Buchan
ERErica Russ
Erica Russ
KBKristy Buist
Kristy Buist
CTCarrie Thomson-Casey
Carrie Thomson-Casey
LVLuke Del Vecchio
Luke Del Vecchio
FNFiona Naumann
Fiona Naumann
Work-Integrated Learning (WIL) is a pedagogical approach that bridges academic learnings with professional experiences. Within health, WIL is commonly a core element of the pedagogy occurring in the form of industry placement. In one regional Australian university’s health faculty, WIL is managed by WIL Academic Coordinators (WILACs). This role extends beyond management of WIL, also incorporating substantial preparation and support of students, stakeholder engagement, and awareness of the overall program to support scaffolded experiences. In 2023, a WILAC Community of Practice (CoP) was formed in the health faculty, to support sharing of practices, professional identity, and foster a community of learning and scholarship. Through this CoP, it was identified that programs were experiencing similar challenges, significant diversity in practices existed, and there were key opportunities for improvement. As such, a Quality Assurance process was undertaken, to understand current practices across programs and identify best practices, opportunities for collaboration, and key areas to address at program- and faculty-wide levels. The Quality Assurance was guided by an existing framework centred on four key domains of practice: student experience; curriculum design; institutional requirements; and stakeholder engagement. This practice report outlines the process undertaken, initial learnings, and applications to future practice, within and beyond health.

19 November 2017 in JMIR Preprints
Verified
Preprint
Open access
JZJiemin ZHU
Jiemin ZHU
LELyn Ebert
Lyn Ebert
XLXiangyu Liu
Xiangyu Liu
DWDi Wei
Di Wei
Sally Wai Chi ChanSally Wai Chi Chan
Sally Wai Chi Chan
BACKGROUND Women undergoing chemotherapy for the treatment of breast cancer have frequently reported unmet supportive care needs. Moreover, easily accessible and innovative support is lacking. OBJECTIVE The purpose of this trial was to determine the effectiveness of an app-based breast cancer e-support program to address women’s self-efficacy (primary outcome), social support, symptom distress, quality of life, anxiety, and depression. Secondary objectives included exploring the association between women’s health outcomes and the breast cancer e-support usage data. METHODS A multicenter, single-blinded, randomized controlled trial was conducted. A total of 114 women with breast cancer, who were commencing chemotherapy and were able to access internet through a mobile phone, were recruited in the clinics from 2 university-affiliated hospitals in China. Women were randomized either to the intervention group (n=57) receiving breast cancer e-support plus care as usual or the control group (n=57) receiving care as usual alone. The health care team and research assistants collecting data were blinded to the women’s group allocation. Bandura’s self-efficacy theory and the social exchange theory guided the development of the breast cancer e-support program, which has 4 components: (1) a Learning forum, (2) a Discussion forum, (3) an Ask-the-Expert forum, and (4) a Personal Stories forum. Moderated by an experienced health care professional, the breast cancer e-support program supported women for 12 weeks covering 4 cycles of chemotherapy. Health outcomes were self-assessed through paper questionnaires in clinics at baseline before randomization (T0), after 3 (T1), and 6 months (T2) of follow-ups. RESULTS Fifty-five participants in the intervention group and 49 in the control group completed the follow-up assessments (response rate: 91.2%). During the 12-week intervention, the log-in frequency ranged from 0 to 774 times (mean 54.7; SD 131.4; median 11; interquartile range, IQR 5-27), and the total usage duration ranged from 0 to 9371 min (mean 1072.3; SD 2359.5; median 100; IQR 27-279). Repeated measures multivariate analysis of covariance (intention-to-treat) found that breast cancer e-support + care as usual participants had significant better health outcomes at 3 months regarding self-efficacy (21.05; 95% CI 1.87-40.22; P=.03; d=0.53), symptom interference (−0.73; 95% CI −1.35 to −.11; P=.02; d=−0.51), and quality of life (6.64; 95% CI 0.77-12.50; P=.03, d=0.46) but not regarding social support, symptom severity, anxiety, and depression compared with care as usual participants. These beneficial effects were not sustained at 6 months. Spearman rank-order correlation showed that the breast cancer e-support usage duration was positively correlated with self-efficacy (r=.290, P=.03), social support (r=.320, P=.02), and quality of life (r=.273, P=.04) at 3 months. CONCLUSIONS The breast cancer e-support program demonstrated its potential as an effective and easily accessible intervention to promote women’s self-efficacy, symptom interference, and quality of life during chemotherapy. CLINICALTRIAL Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12616000639426; www.ANZCTR.org.au/ACTRN12616000639426.aspx (Archived by Webcite at http://www.webcitation.org/6v1n9hGZq)